Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.

Br J Cancer · 2013 · PMC3833226 · PMID 24129234

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A clear trend towards an inhibition of migration capability was also observed for U-2OS/DX580, Saos-2, and Saos-2/DX580, whereas IOR/OS18, U-2OS, and U-2OS/MTX300 did not show any response to VX-680 treatment ( Supplementary Figure S2A ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.